Affirmed Therapeutics BV (NASDAQ:AFMD) shares were down 4.3% during trading on Wednesday . The stock traded as low as $2.45 and last traded at $2.47, with a volume of 70,182 shares trading hands. The stock had previously closed at $2.58.

Several research analysts recently commented on AFMD shares. Jefferies Group reduced their price target on Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Thursday, May 19th. Leerink Swann cut Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 19th. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Affirmed Therapeutics BV in a research report on Wednesday, May 18th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $8.63.

The firm’s market capitalization is $84.05 million. The stock’s 50 day moving average price is $2.80 and its 200-day moving average price is $3.40.

Affirmed Therapeutics BV (NASDAQ:AFMD) last issued its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.05. The business earned $2.07 million during the quarter, compared to analysts’ expectations of $2.10 million. During the same period in the prior year, the company earned ($0.19) earnings per share. The business’s quarterly revenue was down 6.4% on a year-over-year basis. Equities analysts anticipate that Affirmed Therapeutics BV will post ($1.12) EPS for the current year.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.